CAS No.:75330-75-5

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	17mg/kg/3W-I (17mg/kg)	BEHAVIORAL: WAKEFULNESS	Lancet. Vol. 343, Pg. 973, 1994.
human	TDLo	oral	8750ug/kg/14D (8.75mg/kg)	BEHAVIORAL: WAKEFULNESS BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)	Clinical Pharmacology and Therapeutics Vol. 50, Pg. 730, 1991.
man	TDLo	oral	240mg/kg/60W- (240mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS	Annals of Pharmacotherpy. Vol. 26, Pg. 190, 1992.
mouse	LD50	oral	> 1gm/kg (1000mg/kg)		Journal of Antibiotics. Vol. 32, Pg. 852, 1979.
women	TDLo	oral	285mg/kg/30W- (285mg/kg)	LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), ZONAL" LIVER: LIVER FUNCTION TESTS IMPAIRED SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Israel Journal of Medical Sciences. Vol. 28, Pg. 101, 1992.

Consensus Reports：

 

SAFETY PROFILE：

Hazard Codes of Lovastatin (CAS NO.75330-75-5): Xi
Risk Statements: 36/37/38 
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 22-24/25-36/37/39-26 
S22:Do not breathe dust. 
S24/25:Avoid contact with skin and eyes. 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RIDADR: 3077
WGK Germany: 3
RTECS: EK7907000
HazardClass: 9
PackingGroup: III

Standards and Recommendations：

 

Analytical Methods：